Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis Posts 63.7% Profit Surge
05:16pm, Tuesday, 11'th Feb 2025
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings.
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 11'th Feb 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key cor
2 Stocks to Buy With Less Than $40
09:00am, Monday, 10'th Feb 2025
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look excit
EXEL or TECH: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 06'th Feb 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to v
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
11:36am, Thursday, 06'th Feb 2025
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:21am, Thursday, 06'th Feb 2025
Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:46am, Wednesday, 29'th Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 28'th Jan 2025
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
01:40pm, Monday, 27'th Jan 2025
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the a
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination wi
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine t
Revenues, Treatment Pipeline Driving Exelixis Higher
07:44am, Wednesday, 22'nd Jan 2025
Shares of oncology company Exelixis, Inc. (EXEL) gaining on rising revenue, pipeline progress.
EXEL vs. TECH: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 21'st Jan 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking for u
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
10:36am, Tuesday, 21'st Jan 2025
Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
01:16pm, Tuesday, 14'th Jan 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
